Eli Lilly said on Thursday that India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to compete with Novo Nordisk's recently launched Wegovy.

With Novo Nordisk’s Wegovy already in the market, Eli Lilly is stepping up its game with a patient-friendly pen device, intensifying the race for India's booming obesity drug market.

Wegovy, the ₹26K/month weight-loss jab, hits India with bold promises—from fat loss to heart health. But is this pharma fix a miracle, a muscle-risk, or just a rich man’s diet?